<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
71124-0039-1
</NDCCode>
<PackageDescription>
16 mL in 1 VIAL, GLASS (71124-0039-1)
</PackageDescription>
<NDC11Code>
71124-0039-01
</NDC11Code>
<ProductNDC>
71124-0039
</ProductNDC>
<ProductTypeName>
DRUG FOR FURTHER PROCESSING
</ProductTypeName>
<ProprietaryName/>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Bevacizumab
</NonProprietaryName>
<DosageFormName>
INJECTION
</DosageFormName>
<RouteName/>
<StartMarketingDate>
20240924
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
DRUG FOR FURTHER PROCESSING
</MarketingCategoryName>
<ApplicationNumber/>
<LabelerName>
Samsung BioLogics Co. LTD
</LabelerName>
<SubstanceName>
BEVACIZUMAB-ADCD
</SubstanceName>
<StrengthNumber>
25
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes/>
<DEASchedule/>
<Status>
Unfinished
</Status>
<LastUpdate>
2025-10-28
</LastUpdate>
<PackageNdcExcludeFlag/>
<ProductNdcExcludeFlag/>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
24-SEP-24
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage/>
</NDC>